Oral propranolol therapy for infantile hemangiomas

Oral propranolol therapy for infantile hemangiomas - Oral propranolol therapy for infantile hemangiomas

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007664

Enrollment

Registered

2012-05-01

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile hemangiomas

Interventions

Oral propranolol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Proliferating infantile hemangiomas 2.Informed consent

Exclusion criteria

Exclusion criteria: 1.Patient who has a severe complication without infantile hemangiomas 2.Patient with the past of serious side effect by the propranolol drug 3.Patient with asthma or carbohydrate metabolism 4.Patient who was considered ineligible by the investigators

Design outcomes

Primary

Measure	Time frame
Change in size of infantile hemangiomas and side effects of propranolol treatment	—

Countries

Japan

Contacts

Public ContactKazuhide Mineda

Tokushima University Hospital Plastic and Reconstructive Surgery

mineda.k528@gmail.com088-633-7296

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026